Abbott Laboratories (ABT) Cash from Investing Activities (2009 - 2026)

Abbott Laboratories' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$20.3 billion for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 4224.26% year-over-year to -$20.3 billion; the TTM figure through Mar 2026 stood at -$22.3 billion (down 834.79% YoY), while the FY2025 annual figure was -$2.4 billion, down 3.59% from the prior year.
• Cash from Investing Activities came in at -$20.3 billion for Q1 2026 at Abbott Laboratories, down from -$913.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$264.0 million in Q2 2022 to a low of -$20.3 billion in Q1 2026.
• A 5-year average of -$1.8 billion and a median of -$582.0 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 62.65% in 2024 and tumbled 4224.26% in 2026, its largest moves.
• Abbott Laboratories' Cash from Investing Activities stood at -$632.0 million in 2022, then plunged by 30.38% to -$824.0 million in 2023, then declined by 5.1% to -$866.0 million in 2024, then fell by 5.43% to -$913.0 million in 2025, then tumbled by 2126.07% to -$20.3 billion in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$20.3 billion, -$913.0 million, and -$457.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison